Incyte Corporation (INCY)
$
60.55
-0.05 (-0.08%)
Key metrics
Financial statements
Free cash flow per share
1.1355
Market cap
11.7 Billion
Price to sales ratio
2.7629
Debt to equity
0.0126
Current ratio
1.9728
Income quality
10.2817
Average inventory
64.7 Million
ROE
0.0087
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Incyte Corporation is a biopharmaceutical company that concentrates on the discovery, development, and commercialization of proprietary therapeutics both in the United States and internationally. The EBITDA is $408,158,000.00 a key indicator of the company's operational profitability. The gross profit stands at $3,929,149,000.00 highlighting the company's profitability from core operations. Among its noteworthy products, Incyte offers JAKAFI, which is utilized for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that serves as an oncogenic driver in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor designed to treat chronic myeloid leukemia as well as Philadelphia-chromosome positive acute lymphoblastic leukemia. Furthermore, the company provides a range of clinical stage products, such as ruxolitinib for steroid-refractory chronic graft-versus-host disease (GVHD), itacitinib in Phase II/III clinical trials for naive chronic GVHD, and pemigatinib for treating bladder cancer, cholangiocarcinoma, and tumor-agnostic conditions. The company's stock is identified with the symbol 'INCY' in the market, and it reported an income before tax of $316,630,000.00 showcasing its pre-tax profitability. Additionally, the operating income ratio is 0.01 indicating the company's operational profitability margin. Incyte also collaborates with various pharmaceutical companies to expand its research and development efforts. With a mid-range market capitalization of $11,717,878,200.00 Incyte is a steady performer in the biopharmaceutical sector. The stock is reasonably priced at $59.99 appealing to a broad range of investors. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape. Moreover, the stock has a high average trading volume of 1,792,291.00 indicating strong liquidity. As part of the Healthcare sector, the company drives innovation and growth, continuously working on new therapies and treatment options. Its collaborations with leading companies in the field and numerous clinical trials underscore its commitment to advancing medical science and improving patient outcomes in challenging diseases.
What is Incyte Corporation (INCY)'s stock forecast?
Analysts predict Incyte Corporation stock to fluctuate between $50.35 (low) and $83.95 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Incyte Corporation's market capitalization?
As of 2025-04-01, Incyte Corporation's market cap is $11,717,878,200, based on 193,524,000 outstanding shares.
How does Incyte Corporation compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Incyte Corporation has a Lower Market-Cap, indicating a difference in performance.
How can I buy Incyte Corporation (INCY) stock?
To buy Incyte Corporation (INCY) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for INCY. Place an order (Market, Limit, etc.).
What is the best time to invest in Incyte Corporation?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did Incyte Corporation perform in the last earnings report?
Revenue: $4,241,217,000 | EPS: $0.16 | Growth: -94.01%.
Where can I find Incyte Corporation's investor relations reports?
Visit https://www.incyte.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Incyte Corporation?
You can explore historical data from here
What is the all-time high and low for Incyte Corporation stock?
All-time high: $94.50 (2021-02-09) | All-time low: $50.27 (2023-10-31).
What are the key trends affecting Incyte Corporation stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
seekingalpha.com
Statistical significance achieved with both doses of povorcitinib in both phase 3 STOP-HS studies treating patients with Hidradenitis suppurativa. The global Hidradenitis Suppurativa market size is expected to be worth $1.57 billion by 2031; Incyte can do well in biologic experienced HS patients. Regulatory discussions possible of expanded approval of OPZELURA for Prurigo Nodularis patients; However, regulatory discussion will be needed to determine if one phase 3 study will be enough for filing.
investopedia.com
Shares of Incyte (INCY) sank nearly 10% Monday, making it the biggest decliner in the S&P 500 after the release of its latest clinical trial.
barrons.com
The biopharmaceutical company announces positive results from two skin disease treatment studies. But Wall Street doesn't think it was enough.
schaeffersresearch.com
Incyte Corp (NASDAQ:INCY) stock is down 11.4% to trade at $60.16 at last glance, after the pharmaceutical company's phase three trial data for its skin disease treatment showed it was only effective for half of participants.
zacks.com
Incyte reports positive data from two phase III studies evaluating Opzelura for prurigo nodularis in adults.
businesswire.com
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #AAD2025--Incyte Announces Results of Phase 3 Clinical Trials Evaluating Ruxolitinib Cream 1.5% (Opzelura®) in Patients with Prurigo Nodularis (PN).
businesswire.com
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
businesswire.com
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #AAD2025--Incyte to Unveil New Data from its Dermatology Portfolio at 2025 American Academy of Dermatology (AAD) Annual Meeting.
zacks.com
Incyte reports mixed fourth-quarter 2024 results as earnings miss estimates while revenues beat the same. Jakafi and Opzelura drive year-over-year sales.
seekingalpha.com
Incyte Corporation (NASDAQ:INCY ) Q4 2025 Earnings Conference Call February 10, 2025 8:00 AM ET Company Participants Ben Strain - Associate Vice President, Investor Relations Herve Hoppenot - Chief Executive Officer Pablo Cagnoni - President, Head of Research & Development Christiana Stamoulis - Chief Financial Officer Matteo Trotta - Executive Vice President, General Manager, U.S. Dermatology Conference Call Participants Tazeen Ahmad - Bank of America David Lebowitz - Citibank Jessica Fye - JPMorgan Salveen Richter - Goldman Sachs James Shin - Deutsche Bank Vikram Purohit - Morgan Stanley Marc Frahm - TD Cowen Kelly Shi - Jefferies Brian Abrams - RBC Capital Markets Jay Olson - Oppenheimer Matt Phipps - William Blair Andrew Berens - Leerink Partners Andy Chen - Wolfe Research Salim Sayed - Mizuho Evan Seigerman - BMO Capital Markets Srikripa Devarakonda - Truist Securities Operator Greetings, and welcome to the Incyte Fourth Quarter 2024 and Full Year Financial and Corporate Update Conference Call and Webcast. At this time all participants are in listen-only mode.
See all news
